Related Experiment Video
Updated: Jan 13, 2026
An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract
Published on: July 1, 2020
Characterisation of Antifungal Prophylaxis and Therapy Among Inpatients With Haematological Malignancies in
Criscuolo Marianna1, Bonanni Matteo2,3, Martino Giordana4
1Dipartimento di Laboratorio e Scienze Ematologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.
Background:
Invasive fungal infections (IFI) are a prominent cause of morbidity and mortality among patients with haematological malignancies (HMs). Diagnostic work-up excluding IFI is mandatory in case of persistent fever while antifungal treatment (AFT) is started.
Objectives:
We aimed to describe antifungal prophylaxis (AFP) and AFT among haematological patients with IFI managed in clinical practice, focusing on microbiological and radiological characteristics, 30-day outcome and therapeutic options after AFT failure.
Patients And Methods:
We enrolled 461 consecutive adult and paediatric patients with HMs, in which an intravenous AFT was started from September 2019 to December 2021. After serum galactomannan (GM) and chest CT scan, they were stratified as presenting with proven, probable, and possible IFI according to 2008 EORTC-MSG criteria. Fungal isolates were detected from culture tests in 17.5% and from biopsy in 1.5% of patients. Mould active and non-active AFP was used in 42.3% and 16.5% of cases, respectively.
Results:
Use of AFP significantly impact on serum GM negativity (p < 0.001 for mould active and p = 0.04 for mould non active, respectively). Use of mould non-active prophylaxis significantly correlates with radiological imaging (typical p = 0.0037, IC (0.370-0.825) and negative -p = 0.0031, IC (0.241-0.750)). Toxicity, progression, and drug interaction were responsible for therapy change in 58 (12%) patients: 18 patients with proven/probable IFI needed multiple courses of AFT. At 30 days from starting AFT, overall mortality with IFI was 23/461 (5%).
Conclusions:
In this observational study, we recorded an impact of AFP on serum GM results and radiological imaging. Need of AFT should be carefully evaluated, as diagnostic work-up might be affected not only by specific disease risk but also by previous AFP.
Insights
Antifungal prophylaxis (AFP) impacts diagnostic tests for invasive fungal infections (IFI) in hematological malignancy patients. Careful evaluation of antifungal treatment (AFT) is crucial, considering prior AFP use.
Area of Science:
- Hematology
- Infectious Diseases
- Medical Mycology
Background:
- Invasive fungal infections (IFI) are a significant cause of mortality in patients with hematological malignancies (HM).
- Diagnostic work-up is essential for persistent fever, often preceding antifungal treatment (AFT).
Purpose of the Study:
- To describe antifungal prophylaxis (AFP) and AFT practices in HM patients with IFI.
- To analyze microbiological and radiological characteristics, 30-day outcomes, and AFT failure management.
Main Methods:
- 461 adult and pediatric HM patients receiving intravenous AFT from 2019-2021 were enrolled.
- Patients were stratified using EORTC-MSG criteria based on serum galactomannan (GM) and chest CT scans.
- Fungal isolates were identified via culture (17.5%) and biopsy (1.5%).
Main Results:
- AFP use significantly impacted serum GM negativity (p < 0.001 for active, p = 0.04 for non-active).
- Mould-non-active prophylaxis correlated with typical (p = 0.0037) and negative (p = 0.0031) radiological imaging.
- 58 patients (12%) required AFT changes due to toxicity, progression, or drug interactions; 18 needed multiple AFT courses. Overall 30-day mortality was 5% (23/461).
Conclusions:
- AFP influences serum GM results and radiological imaging in HM patients.
- The need for AFT requires careful evaluation, as diagnostic work-up can be affected by prior AFP.
- Diagnostic strategies should account for both disease risk and previous antifungal prophylaxis.
Related Concept Videos
01:29Therapeutic Drug Monitoring: Affecting Factors
02:56Treatment Resistant Cancers